Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Trial

@article{Rickels2008EffectsOP,
  title={Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled Trial},
  author={Karl E. Rickels and Sanjay J. Mathew and Michael D Banov and Dan L. Zimbroff and Scott Oshana and Edward C Parsons and Stephen Donahue and Michael G. Kauffman and Ganesh R. Iyer and John F. Reinhard},
  journal={Journal of Clinical Psychopharmacology},
  year={2008},
  volume={28},
  pages={235-239}
}
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the possible therapeutic utility in anxiety, a randomized, double-blind, placebo-controlled trial was conducted in 311 subjects who met the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, for generalized anxiety disorder. All subjects underwent a 1-week placebo run-in and were randomized to receive once-daily capsules containing either… 

Non-Antidepressant Treatment of Generalized Anxiety Disorder.

TLDR
Pregabalin and quetiapine are the two most promising non-antidepressant treatments for GAD.

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

TLDR
A lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

  • B. BandelowJ. ZoharE. HollanderS. KasperH. MöllerWFSBP TASK FORCE ON TREATMENT GUIDELINES FOR ANXIE
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2008
TLDR
Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

The role of serotonin receptors in migraine headaches

TLDR
The data on the distinctive distribution of different 5-HT receptors in the trigemino-vascular system and their involvement in the regulation of cerebral vascular tone, as well as in the modulation of pain transmission in peripheral and central structures of the trigEMinal complex are summarized.

Current and emerging drug therapies for the treatment of depression in adults with epilepsy

TLDR
Though promising, the level of evidence provided by these studies is still low as the majority have relevant methodological limitations, and SSRIs are the drug class with the largest amount of data.

Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.

Current awareness in human psychopharmacology

  • Psychology
  • 2008
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography

References

SHOWING 1-10 OF 16 REFERENCES

Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.

TLDR
It is suggested that the effect of buspirone on sexual dysfunction is a result of a reversal of SSRI-induced sexual side effects rather than of an antidepressant effect of the drug.

Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant Response

Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.

TLDR
Fluoxetine is significantly superior to placebo in reducing minor depressive disorder symptoms within a 12-week period, and improvement in psychosocial function with fluoxettine may take longer than 12 weeks.

Tolerability, Pharmacokinetics, and Neuroendocrine Effects of PRX‐00023, a Novel 5‐HT1A Agonist, in Healthy Subjects

TLDR
Single and multiple oral doses of PRX‐00023 were found to be safe and well tolerated in healthy subjects and transiently increased blood prolactin levels 2 to 3 hours after administration, consistent with its mechanism as a 5‐HT1A agonist.

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial.

TLDR
Clinical improvement data showed gepirone's anxiolytic response to be delayed, being significant from placebo beginning at week 6, whereas diazepam caused significantly more relief than placebo from week 1 onward, and taper results showed that onlydiazepam, but not gepIRone, caused a temporary worsening of anxiety symptoms or rebound.

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder

TLDR
Duloxetine 60 mg/day is effective and well tolerated in milder MDD and is consistent with that seen in previous studies of duloxettine in patients with more severe depression.

Buspirone and diazepam in anxiety: a controlled study.

TLDR
Those who improved most were married, well-educated females who had both a positive family adjustment and a low level of depression, while buspirone appears more effective in reducing symptoms associated with cognitive and interpersonal problems.

Placebo Response and Antidepressant Clinical Trial Outcome

TLDR
Responsibility magnitude varies and has an important effect on antidepressant clinical trials, illustrating the need for a placebo arm to determine if the trial was sensitive to treatment differences and highlighting the dangers of cross-study comparisons.